The latest from GRA...

May 8, 2017

Georgia State: Researcher Gets $2.3 Million Grant to Study How to Reduce Tumor Growth in Lung Cancer

By LaTina Emerson, Georgia State University
Dr. Ming-Hui Zou, director of the Center for Molecular & Translational Medicine and a Georgia Research Alliance Eminent Scholar in Molecular Medicine, has received a five-year, $2.3 million federal grant to study how to reduce lung cancer tumor growth.

In the United States, more people die from lung cancer than any other type of cancer, according to the Centers for Disease Control and Prevention. In 2013, the most recent year for which statistics are available, 212,584 people were diagnosed with lung cancer and 156,176 people died from lung cancer.

As cancer develops, tumor cells release substances that promote the formation of new blood vessels, known as pro-angiogenic factors, by stimulating a response from endothelial cells, which line the inner walls of blood vessels. This leads to increased angiogenesis (the formation of new blood vessels), tumor growth and the spread of cancer.

With this knowledge, scientists have developed therapies that target vascular endothelial growth factor (VEGF), a potent angiogenic factor. However, the benefits of anti-VEGF therapies are often temporary because tumors become resistant to this therapy and start inducing new blood vessel formation with other pro-angiogenic factors. As a result, there’s an urgent need to find novel targets for treatment.

This grant from the National Cancer Institute of the National Institutes of Health will help Zou determine the molecular mechanism by which Liver Kinase B1 (LKB1), a tumor suppressor gene, suppresses transcriptional (gene) expression and activity of VEGF, NRP-1 and other pro-angiogenic factors, resulting in a reduction in tumor growth and a restriction in blood supply to tumors.

“The completion of this project will allow us to identify that enhancing LKB1 activity or expression is not only beneficial in suppressing cancer progression/metastasis but also in treating ischemic heart diseases,” Zou said.

The project has three aims. The first aim is to establish if LKB1 leads to decreased VEGF expression through impeding the activation of transcription, the first step of gene expression, in endothelial cells. The second aim is to establish if LKB1 suppresses NRP-1 and other non-VEGF growth factor-mediated angiogenesis in tumor cells. The third aim is to determine the contribution of LKB1 down-regulation of VEGF and NRP-1 within the vascular niche in mice.

An abstract of the grant, 1R01CA213022-01, is available at NIH’s Project RePORTer website.
For more information about the Center for Molecular & Translational Medicine, visit


More info


I was in trouble when my doctor told me that i have been diagnosed with herpes and i know my family will face a serious problem when i am gone i lost hope and wept most of the time, but one day i was surfing the internet i saw Dr. hazzan herbal home contact number online i called him and he guided me. i asked him for solutions and he started the remedy for my health thank God,now everything is fine i am cured by Dr.hazzan herbal medicine am very thankful to Dr. hazzan and very happy with my hobby and family email him on ( CALL/WHATSAPP +2348169340571 can as well cure the following disease;Herpes, Asthma, Cancer, HSV1, & HSV2, Hepatitis B, HIV/AID ETCHave a nice day people.
Comment by Virginia • June 9, 2017 • 12:41 pm

* Required   Privacy statement

191 Peachtree Street, NE, Suite 849  |  Atlanta, Georgia 30303  |  404.332.9770  |  Directions  |  Privacy  |  GRA Venture Fund, LLC
Copyright © Georgia Research Alliance  |  All Rights Reserved